BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 11/02/26
Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)Seeking Alpha • 10/30/26
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline ProgressZacks Investment Research • 10/30/26
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarZacks Investment Research • 10/30/26
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 EarningsZacks Investment Research • 10/29/26
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research • 10/29/26
Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It MattersThe Motley Fool • 10/27/26
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockMarketBeat • 10/26/26
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 10/26/26
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 StudyBusiness Wire • 10/26/26
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?The Motley Fool • 10/25/26
Buy 8 Barron's Big Better Bets (Than T-Bills) Out Of 14 'Safer' October DiviDogsSeeking Alpha • 10/25/26